Clinical Trials Browser

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Carcinoma, Intraductal, Noninfiltrating

Breast Carcinoma In Situ

Triple Negative Breast Neoplasms

Medulloblastoma, Neuroblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Clinical Trials

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

DEBRA

PHACS

OXYTAM

MIRHO

TAILORx

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

CAMBRIA-1

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

OMAHA-015

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

ADEPT

Roll-over Study to Allow Continued Access to Ribociclib

EMBER-4

BabyTEARS

ELEGANT

preEMBER

EMPRESS

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

MNEMOSYNE

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

LoTam

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

AMEERA-3

POWER II

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

e3

SOFT

TEXT

Next MONARCH 1

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

POETIC-A

OVELIA

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study